Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
UCL
3376
uCloudlink Group
UCL
$28.6M
| $145K | ﹤0.01% |
57,205
+11,800
| +26% | +$43.5K |
|
|
SYRS
3377
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $145K | ﹤0.01% |
46,135
+300
| +0.7% | +$964 |
|
3378
Alset
AEI
$43.6M
| $144K | ﹤0.01% |
93,066
+1,600
| +2% | +$2.46K |
|
|
SONN
3379
DELISTED
Sonnet BioTherapeutics
SONN
| $144K | ﹤0.01% |
1,670
+1,578
| +1,715% | +$111K |
|
3380
Elutia
ELUT
$36.2M
| $143K | ﹤0.01% |
60,416
+38,500
| +176% | +$81K |
|
3381
Phathom Pharmaceuticals
PHAT
$742M
| $143K | ﹤0.01% |
+10,000
| New | +$115K |
|
|
CLVR
3382
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
| $143K | ﹤0.01% |
23,588
+4,065
| +21% | +$33.1K |
|
3383
Korro Bio
KRRO
$197M
| $142K | ﹤0.01% |
8,184
+454
| +6% | +$8.81K |
|
3384
Key Tronic
KTCC
$41.9M
| $142K | ﹤0.01% |
25,060
-2,440
| -9% | -$14.8K |
|
3385
Research Solutions
RSSS
$74.6M
| $142K | ﹤0.01% |
69,400
-10,018
| -13% | -$21K |
|
|
HLTH
3386
DELISTED
Cue Health Inc. Common Stock
HLTH
| $142K | ﹤0.01% |
384,900
+177,800
| +86% | +$152K |
|
|
GTH
3387
DELISTED
Genetron Holdings Limited ADS
GTH
| $142K | ﹤0.01% |
50,833
-2,134
| -4% | -$5.95K |
|
|
EZGO
3388
EZGO Technologies
EZGO
$2.81M
| $141K | ﹤0.01% |
+1
| New | +$237K |
|
|
FRMM
3389
Forum Markets
FRMM
$81.8M
| $140K | ﹤0.01% |
632
+28
| +5% | +$6.31K |
|
3390
CareCloud
CCLD
$104M
| $140K | ﹤0.01% |
47,600
+7,300
| +18% | +$23.1K |
|
|
HEPA
3391
DELISTED
Hepion Pharmaceuticals
HEPA
| $140K | ﹤0.01% |
267
-17
| -6% | -$10.4K |
|
3392
Hecla Mining
HL
$12.2B
| $140K | ﹤0.01% |
+27,200
| New | +$155K |
|
3393
Magyar Bancorp
MGYR
$123M
| $139K | ﹤0.01% |
13,400
-2,089
| -13% | -$21.5K |
|
|
SIEN
3394
DELISTED
Sientra, Inc.
SIEN
| $139K | ﹤0.01% |
47,270
+19,700
| +71% | +$35.1K |
|
3395
2x Long VIX Futures ETF
UVIX
$202M
| $137K | ﹤0.01% |
+15
| New | +$292K |
|
|
SNCE
3396
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $137K | ﹤0.01% |
32,265
+13,161
| +69% | +$74.6K |
|
3397
Abeona Therapeutics
ABEO
$425M
| $135K | ﹤0.01% |
33,537
-3,300
| -9% | -$11.5K |
|
3398
CervoMed
CRVO
$41.5M
| $135K | ﹤0.01% |
26,873
+800
| +3% | +$4.65K |
|
3399
Gray Media Inc
GTN.A
$612M
| $135K | ﹤0.01% |
14,900
-200
| -1% | -$1.68K |
|
|
IOBT
3400
DELISTED
IO Biotech
IOBT
| $135K | ﹤0.01% |
69,100
+7,400
| +12% | +$14.5K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.